ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation

Ma, Changju; Zhang, Xin; Mo, Xiaomin; Yu, Yaya; Xiao, Zhenzhen; Wu, Jingjing; Ding, Lina; Lei, Chenjing; Zhu, Yanjuan*; Zhang, Haibo*广东省人民医院; 广州中医药大学
PHYTOMEDICINE2024-3DOI: 10.1016/j.phymed.2024.155351
12阅读
引用收藏
分享

摘要

Background: Autophagy, a cellular process involving lysosomal self-digestion, plays a crucial role in recycling biomolecules and degrading dysfunctional proteins and damaged organelles. However, in non-small cell lung cancer (NSCLC), cancer cells can exploit autophagy to survive metabolic stress and develop resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which reduce treatment efficacies. Currently, most studies have found that late-stage autophagy inhibitors can hinder EGFR-TKIs resistance, while research on early-stage autophagy inhibitors is still limited. Purpose: This study investigates the mechanism via which the Xie-Bai-San (XBS) formula enhances NSCLC cell sensitivity to gefitinib, revealing the relationship between XBS-induced cell death and the inhibition of autophagosome formation. Methods: Cell viability was assessed using CCK-8 and EdU assays, lentivirus transfection was utilized to generate PC9 cells harboring the PIK3CA E545K mutation (referred to as PC9-M), autophagic flux was monitored using mCherry-GFP-LC3 adenovirus. Protein expression and colocalization were observed through immunofluorescence staining. The interaction between Bcl-2 and Beclin-1 in PC9-GR and PC9-M cells was determined via coimmunoprecipitation (Co-IP) assay, cell apoptosis was assessed by flow cytometry and PI staining, and overall survival analysis of lung adenocarcinoma patients was conducted using the TCGA database. In vivo experiments included a patient-derived xenograft (PDX) model with EGFR and PIK3CA mutations and subcutaneous mice xenografts of NSCLC cell lines (PC9 and PC9-GR). In addition, autophagic vesicles in mouse tumor tissues were observed via transmission electron microscopy analysis. Results: XBS effectively inhibits the proliferation of gefitinib-resistant NSCLC cells and induces apoptosis both in vitro and in vivo. Mechanistically, XBS suppresses gefitinib-induced autophagic flux by inhibiting autophagy through the upregulation of p-mTOR and Bcl-2 and downregulation of Beclin-1. Additionally, XBS enhances the interaction between Bcl-2 and Beclin-1, and the overexpression of Beclin-1 promotes NSCLC cell proliferation and counteracts XBS-induced cell death, while XBS demonstrates minimal impact on autophagosome-lysosome fusion or lysosome function. Conclusion: This study reveals a novel role for the XBS formula in impeding autophagy initiation and demonstrates its potential as a candidate drug to counteract autophagy-induced treatment resistance in NSCLC.

学科与关键词

关键词
NSCLCXie-Bai-SanAutophagyApoptosisDrug resistance
相关
加载中…
  • Identification of Fangjihuangqi Decoction as a late-stage autophagy inhibitor with an adjuvant anti-tumor effect against non-small cell lung cancer
    Chen, Qiugu; Liao, Yuan; Liu, Yujiao; Song, Yue; Jiang, Junbo; Zhang, Zhen; Li, Anqi; Zheng, Mengyi; Chen, Xiaoyi; Zhao, Tingxiu; Gu, Jiangyong; Tan, Yuhui; Liu, Xiaoyi; Jiang, Yanjun; Wang, Kun; Yi, Hua*; Xiao, Jianyong*; Hu, Shan*Chinese Medicine, 2023, 18(1): 68.
  • BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells
    Yu, Yaya; Xiao, Zhenzhen; Lei, Chenjing; Ma, Changju; Ding, Lina; Tang, Qing; He, Yihan; Chen, Yadong; Chang, Xuesong; Zhu, Yanjuan*; Zhang, Haibo*BMC CANCER, 2023, 23(1): 732.
  • Reduction in gefitinib resistance mediated by Yi-Fei San-Jie pill in non-small cell lung cancer through regulation of tyrosine metabolism, cell cycle, and the MET/EGFR signaling pathway
    Yang, Cai-Zhi; Guo, Wei; Wang, Yi-Fan; Hu, Lei-Hao; Wang, Jing; Luo, Jia-Min; Yao, Xiao-Hui; Liu, Shan; Tao, Lan-Ting; Sun, Ling-Ling*; Lin, Li-Zhu*Journal of Ethnopharmacology, 2023, 314: 116566.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
PHYTOMEDICINE
发表日期
2024-03
卷期
第 125 卷
页码
155351
DOI
10.1016/j.phymed.2024.155351
语言
GERMAN
成果收录
SCIE
资助标注
National Natural Science Foundation of China (NSFC) [82174455, 82374213, 82305337]; Guangzhou Municipal Science and Technology Bureau, China [2023A03J0757, 2023A03J0244]; Traditional Chinese Medicine Bureau of Guangdong Province [20231095]; Guangdong Provincial Science and Technology Innovation Strategy Special Fund (Guangdong -Hong Kong -Macau Joint Lab) [MY2022KF06, 2020B1212030006]; Science and Technology Planning Project of Guangzhou [202201020320]; Major Innovation Technology Construction Project of Synergistic Chinese Medicine and Western Medicine of Guangzhou [2023-2318]

作者

  • M

    Ma, Changju (第一作者)

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • Z

    Zhang, Xin

    2 · guangzhou univ chinese med

查看全部 10 位作者收起作者
  • M

    Mo, Xiaomin

    2 · guangzhou univ chinese med

  • Y

    Yu, Yaya

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • X

    Xiao, Zhenzhen

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • W

    Wu, Jingjing

    2 · guangzhou univ chinese med

  • D

    Ding, Lina

    2 · guangzhou univ chinese med

  • L

    Lei, Chenjing

    2 · guangzhou univ chinese med

  • Z

    Zhu, Yanjuan (通讯)

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • Z

    Zhang, Haibo (通讯)

    guangdong prov hosp · 2 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417